PT Sinar Mas Agro Resources and Technology Tbk (SMAR)
IDX IDX Primary 
XFRA Summary
SMAR Chart
PT Sinar Mas Agro Resources and Technology Tbk (SMAR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has PT Sinar Mas Agro Resources and Technology Tbk ever had a stock split?
PT Sinar Mas Agro Resources and Technology Tbk Profile
| Biotechnology Industry | Healthcare Sector | Adele Sommerfeld CEO | IDX Exchange | ID1000101504 ISIN |
| US Country | 9 Employees | 5 Jun 2026 Last Dividend | 20 Jun 2005 Last Split | 19 Dec 1996 IPO Date |
Overview
AVAX Technologies, Inc. stands as a pioneering biopharmaceutical entity, committed to the advancement of autologous cell vaccine technologies aimed specifically at combating cancer. Initially known as Walden Laboratories, Inc., the company embraced a new identity as AVAX Technologies, Inc. in March 1996, marking a pivotal shift in its strategic focus. Since its inception in 1990, AVAX has been dedicated to the exploration and development of innovative treatment solutions, maintaining its headquarters in Philadelphia, Pennsylvania. With a firm stance in the developmental stage, the company's efforts have been channeled towards bringing groundbreaking cancer vaccines from the realm of research into clinical application.
Products and Services
- M-VAX for Melanoma
- O-VAX for Ovarian Cancer
- LungVax for Non-Small Cell Lung Cancer
M-VAX represents a significant stride forward in the treatment of melanoma, having successfully completed phase II clinical trials. This product epitomizes AVAX Technologies' commitment to harnessing the power of autologous cell vaccine technologies in the fight against cancer, offering new hope for patients battling this form of skin cancer.
O-VAX, another innovative product candidate, has also concluded phase II clinical trials, targeting the treatment of ovarian cancer. This development underscores the company's dedication to expanding the therapeutic options available to individuals facing ovarian cancer, leveraging state-of-the-art vaccine technology for improved patient outcomes.
In addition to its melanoma and ovarian cancer vaccine candidates, AVAX Technologies is in the process of developing LungVax, aimed at addressing non-small cell lung cancer. This initiative reflects the company's ongoing efforts to broaden its impact within the oncology field, striving to introduce effective treatment solutions for a range of cancer types.
